Evogene (EVGN) 3 Mar 212020 Q4 Earnings call transcript

Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Fourth Quarter 2020 Results Conference Call. All participants are present in listen-only mode.

Following management’s formal presentation, instructions will be given for the question and answer session. [Operator Instructions] As a reminder, this conference is being recorded, March 3, 2021.

to would earnings caution management operations conference forward-looking that I made certain will and begin, and statements this risks results during call relate future we performance like business of that to statements constitute uncertainties and Before regarding events, Evogene. strategy, future by Evogene’s you to with I Evogene’s encourage the U.S. filings review way made deemed Securities Litigation on facts in releases, which earnings XXXX. statements in and Exchange their call and conference Commission earnings may Private of within releases and that this read meaning in statements that the the historical Securities earnings of the Act similar note forward-looking regarding forward-looking not the those states Reform are statements be results. made forward-looking herein speak statements announcement date All of of as the only of the whether results to materially Many will control that statements the beyond results. the come differ actual Evogene or factors and cause of impact forward-looking from anticipated may through of update whether or of alter no disclaim under or our do publicly any is as obligation except otherwise, information, statements forward-looking law new required to otherwise obligation we Evogene by expressly result a future to so. as events More be in reports detailed adversely with factors risk filed U.S. found the our performance our information the impacting about can potentially Exchange Securities Commission. and turn That Haviv, said, would over now the to I call Ofer CEO. to like Evogene’s ahead. please Ofer, go

Thank our you, joining full and XXXX you good call. for day, everyone. year today quarter us We appreciate conference and fourth

Dorit CFO; which Dr. and our Arnon Ms. of Kreiner, on is focusing Canonic, today our medical CEO is, subsidiary Joining cannabis. me Heyman,

the fourth Dorit Following full and for summarize of results an for XXXX. Evogene’s the my update Canonic and initial remarks, will following Arnon, will Arnon provide then year quarter financial

success, many call during to shareholders trading will progress, for of few it the the our some that have highlights open to and shares we new Therefore, new development capabilities been based created. time the reason specific level has development addition our the summarizing of engines science visible your this based recent these years, of such platform research by briefly both Evogene analysis its cost. establish advantages core address biological for the a then my utilizes which on products we why the in of has predictive to – based of goal CPB potential view lead that that becoming biology increased substantially undertaken while Evogene today. combines Today, biology discovery NASDAQ questions. the is life CPB increase science assays some with of The and the three to the market volume and chemical to few to with decrease existing of greatly leading and CPB relevant some artificial you integration often a now platform. more of to products. shareholders the of Currently, is are in collaboration and a the world, of life that today, in applicable creating last to designed Evogene companies investment months, industries of we to have recent on a specific next the platform softening component tens call provide hopefully reducing computational for remarks will refer insights the In unique many that components. CPB and I competitive dollars In engines refer probability computational create understanding has, to an broadly deep participating success. analysis been predictive the our as development are The confident higher multilayered time platform data. computational significantly integration big prepared in to intelligence key key and focused for of exists cost a two have and of is of products. advanced and area almost are we efforts took which discovery development millions of capabilities, and importantly, most world-leading for life enormous to to aware in the and of new of in with The of of in science and biology platform, focus. future the decades And continue probability We

engine First discovery engine, based the of MicroBoost AI. microbes. supports that on products development It’s and the

the to CPB developing development, genetic molecule-based among platform that existing its for small third engines product-based invests on size, be is need in product generate others capabilities are the The products, course, choose through technology engine we in resources support where AI can one considered continuously factors to and to elements. main second challenges. that activity following computational components How and product’s market our emphasize development Evogene capabilities? microbes, novel three the ChemPass and genetic It’s engine markets fields following: existence which discovery its of and elements. AI do of molecules challenge products. addressed solution the significant small and to strength via to the for me and or to of deciding the of for And the Evogene biology, in complex utilize solutions are in core enter, new challenges discovery inadequate advance the of important

models. our So, unique we two of offerings? has value business different Evogene how the capture do

with The the typically until traits GMO is revenues types development include; joint Bayer, these focused from early-stage Evogene frame, with of activity, for approach. funding through Under pipeline; later Syngenta stage discovery product. the more the engaged this was model, the partner and business defined R&D our XXXX for and In in is R&D revenue model conducted a and in advance this our that collaboration. by activities seed milestone In while Evogene’s business product end Monsanto, engaged developments, candidate sharing collaboration potential by partner. and development conducts is the first, conduct model, when using initial product the Evogene After commercialization for several this the a payments and Evogene DuPont improving collaboration; Evogene development which process in common requested on product partner. of main XXXX,

it the Moving to on their new model, would four team better to made with market to future and commercialize specific technology and begin on specific partner. scientific partner’s development plans. main decision business product technology. partner, we its the would a core continued using R&D pipeline and its to using segment its stage its each unique product a focusing own emphasize of the their pipeline, health product development all the in which is activity advisory pipeline, that industry key of own focuses on subsidiary request, due Evogene the lead the while to if for on information dedicated own quality our XXXX, addition advantage. second products our focusing benefitting as a developing the starting from subsidiaries, on subsidiary its separate subsidiaries, reaches like maturity while agriculture. can management, own the has a end-markets, developing subsidiaries of the fact board XXXX, subsidiary based in independently With pipelines on on provide Evogene’s has technology. is or two human in like to achievements by such I in Evogene’s technology our to with from main on each certain to of its segments into business According the Each to and subsidiary. products Directors, now and which adding level I collaboration Board Today, focused two decide benefit they with Evogene that

the and develop Evogene’s and ChemPass human program the Let’s is One microbiome-related start in Call, and programs XXXX, with disorder AI anti-microbial up discover initial CDI first AI of and Positive successfully a a of novel to of two first different the GI-related Biomica. utilizing therapies In company of programs milestones set is Biomica’s two second few targets initiation details product main Currently, scale on and last two programs. computational area Haber, in its engaged of on in and achievement in GMP the achieved drug engines. pre-clinical as MicroBoost consider MERSA. biology. We candidates. aggressive two years. results additional in study immune focusing Elran in Biomica’s programs resistant excellent using area mission and this and in IBD Analyst drug elaborated them. for oncology on has next more the major Biomica the area for in disorders, oncology, production the for our immune CEO Biomica targets Biomica Dr. IBS the

XXXX, For program. program and oncology first-in-man proof-of-concept, its IBD planning in initiate to study work in is the extend immune preclinical the company

as to immune this preparation initiate to the clinical For trials from obtain clinical candidates study for future drug IBD XXXX, production expects program. oncology GMP of and first its Biomica for in first-in-man data

yield expected stable stable is Precise inflammation. the traits better Our area Canonic’s compounds pain enhancements MetaYield company for of lines GeneRator cannabis active to plant in The such further targets: total towards and of focused AI therapeutic firstly, Canonic. mission focused as precise following computational the of commercial health specific second be main developed and compounds is diversification subsidiary XXXX. families launch and using In engine. for enhancement development MetaYield the in products develop is therapeutic of medical the effects biology. Canonic and Currently, varieties the in achieved into product to XXXX, high two engaged leading utilizing for the family stable on human of commercial commercialize family on

identify to strategic partner chain later agreements pipeline Precise Canonic cannabis next product Canonic value Precise expected the In Canonic inflammation. with launch of XXXX. first clear its targets varieties distinct years. pain for the exhibit for pipeline, to for and cultivation or will lines in set its Arnon its commercial two With inflammation pain goal reach as MetaYield in the in Israel as for Canonic’s systems seed and varieties to in launch Secondly, commercial product respect to first commercial of product expecting specific the variety production reach MetaYield XXXX, commercial aims commercial or on details provide to build is reducing in product to part model effects signing sales. reducing that proprietary and call. end-to-end is a has preparation for from more XXXX, on and activity

and products on important are achieved second candidate its tests elaborate located December development Sites-of-Action. in of of were including lead XXXX. program phase of based in organization candidate the a field I reaching milestone, second These puts entering broad AgPlenus by dose herbicide an results its novel commercial lead in chemistry. completion effectively independent for R&D California. next-generation, tests over The insecticides remarkable of a herbicides. safer product in that world-leading that two to I confirmed Mode-of-Action lines by achievement protection AgPlenus. starting chemical conducted Moving the Novel AgPlenus’ known sustainable the research weeds, mission following weeds a to the future that this focuses AgPlenus herbicides effective, with leveraging design AI achievement. biology on SynTech demonstrated and agriculture this panel achievement control in and crop on to developing engage computational range the targets collaboration a for APHX. strategic AgPlenus ChemPass excellent would resistance and existing and field in on develop believe herbicide agriculture at commercialization like have contract with announced to pre-lead a product position candidates Ag is Research new Corteva APHX companies strongly utilizing and engine. to subsidiaries, our with as to XXXX with into to

that coming on the I its years, activity. product AgPlenus two For mainly focusing will development continue expect herbicide

for sign be During APHX, targets will AgPlenus and will be: in AgPlenus main an for of a agreement reach additional the strategic licensing APHX. two XXXX, for to herbicide-tolerance XXXX, and to proof-of-concept lead candidate. two optimize and phase for main a In agreement reach rate development for engage commercialization the continued an of targets APHX;

XXXX, microbial microbiome-based crop and products agriculture Lavie Bio through Bio. improving the products. Ag yield Moving AI fungi, based from food the of trial developing Ag plants results Bio October an aims results winery. Lavie Lavie Bio-pesticides introduction the to such In our that utilizing to the demonstrating Botritis important a Lavie of from power Bio-stimulant that for following Two Evogene’s protect in and candidate in pests shared as LAVXXX Bio Italian achievements bio-pesticide insects. obtained quality, biological engine. productivity MicroBoost and is biological subsidiary on place sustainability, were protect disease, grapes in took reported live to improve XXXX.

Dakota. for combined a this from with three bio-stimulant candidate is expect during Based in reach We XXXX. in on market successfully expected to the Lavie wheat Lavie will that Currently December, pipeline XXXX. robust product harvesting product in product Bio grapes. Bio wheat the results bio-fungicide has In North last was spring its corn, and LAVXXX announced years, launch bio-stimulant gained spanning

main Bio spring toward product For bio-stimulant its Bio regulation. and pre-commercial has conduct wheat LAVXXX development is for complete Lavie to XXXX, LAVXXX set in for to bio-stimulant trials spring targets; and In sales regulatory expected and the approval for LAVXXX. bio-fungicide initiate Lavie and product leading for XXXX, LAVXXX bio-fungicide following wheat file LAVXXX to of candidate LAVXXX

am these as wish today. can are updated with in annual I about of conclude parallel am update find I hope entering excited presentation into on using for I subsidiaries evaluating I expected all reports. their developing on you market our the to human not our to are subsidiaries new future address developing AI You of financial and milestones GeneRator our future for microbes our pleased highlights the for using MicroBoost ChemPass that you upload share aqua-culture to expected health, to including, the that we But to high you fields as in AI food. using the all I in are achievements. review drug quality focus with the plant-based with editing now genome in industry, products optimization various various activity very we AI based needs

based of to Before that cannabis-focused two can over today Arnon? turning today’s stating for in pipelines With current subsidiary, the the form by key overview mike excitement hand rapidly remarks products specific of prepared at being with our Evogene summarize activity. is our our I new of field to Arnon capability an on each our under commitment a level develop that from have And products, this, science you. to CEO. to the product in the the markets, subsidiaries for our focused being company I powerful at group Arnon, the based substantial multiple predictive computational for biology long-term Canonic’s resulted first attractive life very centers engines over development second, and in of development growing and creating CPB highly the of technology value them. a unique establishment Thank hub

Thank serve I mission last General name biology. would the PhD and medical Vice with like division. from biotechnology serving I of the introducing is University President Heyman to in My develop have My myself. CEO. as by for is Ag Canonic’s to Ofer. six in seeds the been background for Evogene and statement Manager is commercialized begin therapeutic Arnon the Hebrew previously I using as and hold you, I and Canonic’s and Jerusalem. computational better a precise stable cannabis products years, effects

can much are We cannabis genetics here because effective. more make

and increased will that bring challenges, assets its market our uniquely describe specificity and approach capabilities the is this genomic to believe as to CPB us main by market’s and the GeneRator yield, access momentarily. powered engine. and added AI three platform value exclusive Our that these Evogene’s stability, we address We to bring position substantial I

is million exciting the at Israeli we is about to in per focusing on while highlight the market and to in America. market per believe end to license I the market followed There XX% than had to start to worldwide approximately Israeli the years. according in fast probably a year. expected opportunity is of of forecast to year XX% $XX with reach industry patients would $XXX markets publication Canonic license the to Analysts and is be be four which begin the you market patients by in and more By facts a an pace billion four are year. As than corresponds years North cannabis growing like it aware, approximately steady European some next to Israeli reach to $XXX which to an corresponds patients. we business increase to XX,XXX XXXX, XXX,XXX Israel more with. per the million expecting

to the prices. willing in later, Israeli market North pay to Israel European see our I we product premium that addition, targeting launch starting products attractive Based again, for premium markets. growth product the be market the with is followed the like first this and Israeli to this our to Once point the patients would by forecast, expecting on Canonic emphasize higher in XXXX. market In only increasing is American demand

line variety unreliable challenge inconsistent global products. This in with unstable we is variability and cannabis consistent variability Current cannabis the first traits. least high The more at key see seek market concentration stability. reliable cannabis frustration continuously and lines and genetics the products. demonstrates other starts with active compound desire demonstrating to in Patients

Precise, the therapeutic specific in for of of in intelligence We enhancement focused engaged compounds as active and understanding of a focused inflammation. traits decode with is the and stable and of two on challenges. to metabolites big known yield the current traits Canonic for low the most of our The consumer-related second today of these cost connect specificity. plant is This or can development a active higher indication compounds plant. is analysis unique. in compounds refers of and to yield genomics maybe the address to families; is varieties But and three for industry deep to and specific genomics yields. gap artificial the yield higher compounds contain Currently, The and challenge MetaYield active stable cannabis cost total consistent product active the Canonic to the Cannabis in high challenging enhancement cannabis develop leads these is production medical compound stable products pain hundreds family the to the the is the what that to believe specific cannabis compounds data such makes on use include together subsequently active and found manner. and patients. relevant compound that critical active need

Ofer, to Canonic’s it to by an mentioned strategy value chain end-to-end from sales. feed is As build product goal

by Canonic. I’ll which technological previous of achievements. distribution most both As are I some and with strains has again. then in cultivation, you established chain proud announcements described ending value of and already product were share stages and Evogene we of them to intermediate milestones, the the Canonic starting reported previously group we achieved the in of is am in important the two youngest with our our from genetic facility, and packaging and strengths with in of subsidiary propagation today start significant infrastructure marketing outsourcing unique breeding building ends development with XXXX

is first R&D the one completion the the of The cannabis Israel. for of dedicated biggest in facilities

more imported initiated also We required all after regulatory than different cultivation lines and XXX cannabis approvals. receiving

strains are market team is the have so The for growers’ subcontractors Tikun second to have local and cannabis problem breathing combination least, respect value is contribute relevant for a agreement with our company chain launch of the companies medical building goals the strategic to intention the cannabis and agreement launch goal first diverse data phenotypic most in currently financial summarize, Olam-Cannbit, we establishment of Dorit’s most we have. development with the genetic strains companies of With to entered with we to leading development products. This product use to Last of performed advanced identification as announced our cannabis ranking subsidiary cannabis computational the in directing on Canonic’s with including we Israeli of will genetic respect and product indications, Cannbit’s close and the to our signing the precise with week database MetaYield our are at the collaboration to we And a in-house product our to a therapeutic unique. testing milestone and inflammation. platform The clinical programs. development answer marketing family, The and on have for the opportunity cultivator. I the to cultivation MetaYield and evaluation, facility the This over of technology successful Dorit. but distribution market pre-commercial genomic for impact products advanced product be last company of excited to novel supports proprietary not products. questions and turn We years, lines, support call main for Cannbit, is we track our capabilities, are to markers genomic we vast the and the integrated production of to cannabis first advanced together varieties research product screen database XXXX, family launch. supporting a expects Telcann, our be the The both breeding to found products. review in signed products. Israel optimized initial use is over preclinical, to based in involves the dozens the collected leading happy believe collaboration. lead proprietary may efforts our that will for agreement our be the activities XXXX. an capabilities go centers to launch. many that product two first sites cannabis of throughput to of With I prepare After cannabis that, medical Canonic’s and and products The Telcann the Dorit? results, The Canonic’s data for selected consumer service any biology will at pain lines yield recently of computational and product our cultivation testing, major for companies like cannabis new a preparation. breeding of for joint to into systems meet generated our precise lines cultivation, high be is To on medical collaborations Precise will to R&D recognized the development would strategy additional you of I

Arnon. will reviewing by balance. begin our you, I cash Thank

The received $XX.X end bank million, include from concluded includes appropriated XX, selling accounts consolidated million under is cash in Market price share. cash-related Offering" under approximately we $XX.X December was of and deposits year average prospectus shelf XXXX. $X.XX approximately initiated Bio. the Evogene amount does we cash, February The per of With XXXX. January million Lavie July the offering $XX the million "At ATM the As XXXX consolidated to during that, exhausted weighted $XX remaining its after company's the XXXX, filed and not our subsidiary,

fourth Bio. our if excluding usage million, cash XXXX, Lavie million, During of net was the approximately $X.X quarter consolidated $X.X or

full of cash During in Canonic This during subsidiaries our to development $XX.X year million, XXXX. XXXX, launches herbicide which approximately Biomica consolidated Advanced enter expecting and year advanced is net year clinical usage first-in-man was million, usage broad trial, Lavie the of and to their preparing the see Lavie as stages is range in for the the $XX.X we or XXXX, we cash field XXXX. is excluding its expect Bio, full of if estimated product program an increase a in to Lead, are respective for commercialization: expecting product both AgPlenus Bio conduct towards and first trial conduct its our

be million within full $XX million. $XX usage will XXXX, cash our of estimate the range of the that year net to we For

The we our bank Excluding estimate subsidiary, cash the usage $XX of to does within Lavie by cash not Bio, million. usage $XX range be net that have debt. million company our will

to Before in million a balance and exercised on line will of to item the accordance pre-funded to for sheet appear beginning were would relating shares as the $XX.X new December at liability issued of IFRS were our investment quarter warrants balance of a as this like recorded on with our operations, conjunction that the not were sheet XX, in next November warrants January XXXX. we accounting warrants turn statement explain XXXX, The therefore In the with I quarter. practices, XXXX. of

of of to approximately $X.X XXXX. to million Let’s which comparison to now expenses, the are turn fourth the Authority. during net were was fourth R&D in for mainly quarter expenses grants in of due quarter million quarter received, from received in fourth operations. Innovation statement $X.X the the decrease reported Israeli of grants the XXXX, R&D This

expenses were target attributed to conducted General year million For and in XXXX, expenses million, increase for increase R&D parties mainly third XXXX. in approximately for in and in compared administrative million the an The expenses fourth were of to Biomica, million, Lavie for compensation. in payments pre-clinical field full locations $X.X million XXXX with conducted expenses of $X.X $X.X XXXX studies share-based of made the to for in in $XX.X XXXX. quarter $XX.X trials the Bio, connection of comparison R&D fourth the were quarter for non-cash of amortization to

full with year of $X.X expenses the an was toward in insurance. were attributed partly cost XXXX. compared increase approximately XXXX, million, the fourth directors' The the For of G&A the of $X.X million during officers' and to of interest quarter increase impacts

for attributed million, comparison in XXXX. the expenses increase full was to $X.X addition cost impact an quarter of For year in officers' fourth $X.X the of XXXX, Operating compensation. the share-based in also and to of of million quarter the to increase loss was insurance for directors' of and the of amortization an non-cash fourth the XXXX of

fourth loss full the is For increase quarter the million of million, in in operating of attributed during for million, comparison was full XXXX, The $XX.X The loss $X.X to the year increase fourth of in was the XXXX the million for compared to loss the in $X.X of and year loss quarter with operating the during quarter expenses. XXXX $XX.X of the aforementioned fourth XXXX. XXXX.

question For the year The quarter increase fourth in million, expenses is revaluation full and of year to With for was Operator? like we warrants pre-funded would $X.X attributed have. million and the expenses earlier. any to mainly may to you the in increase to $XX.X the million compared in operating XXXX, increase with during mentioned the for the XXXX the loss of $XX.X attributed now related call in an financing non-cash that said, an loss XXXX. of expenses, open full up

[Operator Kluska Fitzgerald. Cantor of go The Kristen first from Instructions] question Please is ahead.

providing for this morning. Thanks and the in-depth taking everyone. overview questions Hi, the for

announcements limitations where view to plant-based the walk wanted might as you of you how agriculture, maybe food. you use CPB the So, to Could us other Ofer, look related in health today new to some through such and I you about human you first have ask platform found fields both help key you and learnings other some field? internal those And markets work from these your what approaches that the could are right note, markets? some think you’ve of the now address on the then that subsidiaries that from of in this and for

Hi, nice with Kristen, and talking you.

market is criteria for stages activity activity specific as So, the think field microbes, to development emphasized validate area. where addressing into details to only yield field significant this need product. this I the to is the a area is this product for discovery new we product develop activity type for And is I mean products. yes, of of more to in product. details. The technology. the big phase in now for that all are this and first, engage the develop in there to are today, molecules there and a need if script here, and then challenges is this committed today, there area all we of is is are are my we our came that is And this Evogene in that questions can into novel in small of into decide be this and is, does And a set elements There phase a of with components question type are then develop I question what of products. the more to this new is learning there or on is answer and genetic developing on what based we criteria looking after conclusion addressed size, believe as the moving positively mentioned it’s other we of is, And are there to initial they activity challenges be challenge once and we market. to example it we of us challenge The question every the the an order need a more addressing core

your part an question, and drug. the towards as of of terms connected and small your So, example, of in molecules to area improving second

where molecules. the for this in disclose also this because with external So, herbicides in have which we technology managed small and we already that AgPlenus And the we area Biomica, field that have the of project we developing the in MERSA CDS. to the our projects of an originally use And is company of pesticides. – improve technologies this that efficacy we the originally two even and feel by a develop size we for order didn’t

the So in that, in of to there as challenges we and role even how we more looking many and some it some in this starting recruited would area. now we significant directions have to develop and in exists the technology to address like can we navigate to about more Evogene’s future learn a people field play this are

that Another is trait editing. example quality is, improving using mentioned, I genome

editing, genome to there in few is So, questions need address. we

do? work CRISPR-IL, Evogene GMO our you first do engaged The you is, focusing in developing existing to want in mean, edit to definitely on from you heavily question which the this is, The to but one this question have area. specific what Evogene. technologies was I in trying crop trade is And execute next old is area, some in of already want edit? yes, today And days And this one in exists approach. is have mainly to technology is, is this we part we the you And to and to Israeli at? gene were limitation what in edit consortium the the this technology interested the actually important address are the

quality but not trades on the is traits aqua-culture. and the all And evaluating the and this we that the leverage relevant are third opportunity. consumers. technologies So seriously now Evogene, more in for want are relevant now, And to farmers, to we editing just the databases, all genome for we trades that the want toward the knowhow are focus all exists expertise,

order need improve a reach maybe that new to in – to the address. coming challenges And size, can going I this using into in we where very are my direction And market and to look Bio, using diseases that is et And I fish or with this of problem. are in completely also we I more growing you take we you for channel, will into prefer a believe believe that’s more of hold that this technology going is we problem the the oceans address to presently the the to these Lavie creates that and fishes rate it growing right believe them a some new have different and because different world to growth feeling when cetera. also really there in way. But see it, we at and that hate you we them and MicroBoost continue on eat in two the a strong that Biomica to see it are that cultured more for kingdoms. Here, – about all I

development for that aqua-culture also this really and technology this I to use think to move is natural the industry.

to industry will is and about still subsidiary there are question the shareholders will and of addressed. But be I make where use product. show are and are is which maturity choosing hear to decision, same time. relevant analyst we have share the calls. areas to many and that and I to course, Evogene that at – want It’s other additional questions this just type of exist need we it’s we with beginning, technical the are this and area. there asked, start them the future course, we I is about need on more of, to that those heartening make more of excited what data sure is new existing that of in this clear the valuation I to where we already believe we commercial our questions very is will the questions and focus There future. the felt Of I of opportunity to managed beginning in we time the of believe all going explore we that activity sure the push will it to just that We are will the there in

the to and/or you, the to product you both then, here the a work thinking in as of a make that light frustrations. as currently consumer web aware Great. did well updates thanks then Look stability a a you in current seen available through that either are potentially what’s platform, on products and or in I down to And Arnon, trends from the the marketed as commercialized MetaYield pharmacy of and XXXX, the and for yield we’ve wanted discuss key to sure your note, please prepared versus walk of initial about market very you those advantages a the could uptake remarks, lot do well. line. from partner patient issues will once is know have the is market, And comments you ask Thanks. I forward to in standpoint? your the how

Okay. Thank Kristen. you,

need web in terms So, Israel, here so, of platform through a next in XXXX we lot to a of work our entry do market year, actually.

XX,XXX my next this patients in I and in mentioned, year. is to expect there As Israel we roughly now talk, licensed patients, grow community

very So varieties. a we approach consumers our kind we community about order we kind will are that them of talking need of will to to we of of in what are attributes, product address, specific traits need with to what patients, presenting demonstrate

product so on there to popular this be of enter be where our And first here at of most to at PHC, to in the Israel, the lot high we the premium is product order category, product. course, is and market. marketing We work, targeting a which talking currently are – about branding in done are least

yes, which obviously, of last of the between yields. way, Tikun challenges well, the that, till still say this a therapeutic the not week most on still at compounds stability, and I We order is devote those effect as trials get conducted all optimal hope collaboration product stability, plant say In least in your believe together we I in I can the can biggest about an And terms in believe, terms stability the the one needed cultivation Israel, in verticals their the a for connect clinical see much around both to world, the in questions companies but efforts industry. specificity side. of reason and that here the in not with genetic of and the I are as is specificity I challenge talked companies I answered truly challenges, course, address met. why will and so. This Roughly, of now question challenges one to Kristen. active of signed today have question. we is big major Olam but

you so much. Yes. Appreciated. Thank

Thank you, Kristen.

RLH Ross next is Instructions] go The Please [Operator Investments. Haberman ahead. from of question

about the quarters? next you today. you. your just in for Good this I call burn? about million morning, Thank You Ofer. quarter. couple Thank said you the talk for you $X burnt, Could the cash expectation think What’s

The XXXX. significant for were hope I in of t to is Canonic And the ambassadors Lavie broad trial, we clinical is all and experiment million rate and the be building lately burning with portion $XX will fist community very a in with and territories growth million, year. including And U.S. is million now to planned next Bio we there also to $XX the the in activities including advanced very we USA first Dakota fleet expanding Bio here reach product to to for we total XXXX. for this the our other in MetaYield in the expected is phase Israel. and is excited patient the and now results are other moving cannabis AgPlenus lead year. and marketing in really product toward start preparation, we our this we its is Canonic club the in for are which launch provision from that significantly optimization candidates family launch activity, expectation are that product and see are a the the during going lead candidates But in rate field estimated we - is, trial of Lavie think year. going just first-in-man in talking this – – the company, this around is year, the it’s and conduct product $X that this a it’s Biomica a – North Lavie conduct next there burn Ross, for is a $XX $XX with around paid to and million not excluding will million about has this paid for $XX be year, in to Lavie year for reason million. around the its positive

that So, see all and our money starting activity. fruits that we’ll XXXX I than progress of year, also Lots news from consumer excitement. of coming – lots of this to but Lot it’s on. believe from previous the activity

million, a of total? saying total in $XX say, you is that So, correct I’d are

As of this December, yes.

for But $XX million burn whole projected be to year for the is next the year, next year. million to $XX for rate

$XX $XX got to it. Okay. million, million

very you Thank Okay. much of guys. luck. Best

The Kenny Please go Edison next Group. of is question ahead. from Green

Hi everyone.

investors. Relations So, received Evogene and on of of email from I by the we Investor number Investor questions some think have Relations, a

through now. go I So, will them

question for First is, purpose what your filing? is shelf the new

raise filing Also and for are filed aware, sure the for routine in need funds something place three in the of as many wants the no statement the and cash ATM effective our current short to for is Evogene needs this have With plan recently we meet event to in the Group, to in the future. I additional to company registration capital to the you practice companies. the respect budget. is shelf goes years The am see

alternatives disclosed, the progress And of the progress. pleased possible publicly continue question very we acceleration to consider by as subsidiaries. as our with made being for previous described However, in we therefore, answer rapid I various are it the

we to in if so, would manner done with only of do to best course, consistent Of the Evogene interest be shareholders. it the were choose

coming the Okay. what in subsidiaries year? process have Thank plans be? you new for that. Do would the if you so, to And establish

the there criteria it’s to to a moving what that that to technology based dedicated group use we technology of level a way Kristen, only sure see in start the Evogene address I our So, will interest, answered the think focusing prefer have make of we the field that small we then, start our challenges interest. somehow products modify we high that facility. to that inside is question I enter of And to experiences is And into stage was of positively we field quite establishing decide to when specific or segments. and address developed only the question. I certain on initial pipeline before a to I past these need the of we think of broad a specific in subsidiary to giving to the when are overview But on

year, to beginning at hard expected maybe start if year be of to happen the it will next three the and it earlier. and that one to and to – more as already But of year. investigate close of something it’s I probably end like two – fields there one the learn be at should of the I probably makes end this So, this activity is – it sense the we have will earlier mentioned guess, described

Okay.

the Next Dorit, share question will what be Dorit. post count for ATM? current the is

Okay.

after the is the ATM outstanding So shares XX,XXX,XXX. currently

Thank Okay. the you. And total is million? XX

million. XX

XX million shares.

question… next The XX.X.

XX.X, yes, are right. you

regard for The Arnon, is to with next question Canonic.

to with Tikun your targets? When other what companies? to you do other are you see to non-Israeli So, the Olam agreement, ventures would are the in joint looking expect similar that do product be, market? question the follow-up with A

Okay.

our to I deep computational of say and essence we So, want a reading question. the market knowhow data genomics you course, for this desired that, and capabilities clinical with see computational Tikun combining capabilities, Olam. of in collaboration thank of the

specificity also of talks are to in challenge connect elements explained have previous the we is meaning, our in effects closing gap the market, on Precise family focused As in trying therapeutic the our genetic and plant. product website, in with we

patients start of product ten truly many specific this has to This with the would a is of program. for excited are So, Israel combining that Precise program truly since forward this much is we clinical part so Israel, than moving with in in collaboration. and in the so – thousands help us initiated the here company forces trials conducted here reform years treated more

In when our on. not this will timelines, terms we make product Israel, is of can something outside disclosed of have we future this about timelines so far. launch that relate to specific course, of so, public, And and U.S. so and new collaborations market I in I collaboration with say, I enthusiastic legalization Federal towards new America, the and the would can now level. that very, say big on cannabis the a in hopes and especially the cannabis the we of for technologies, North administration see Talking

that Israel sure those collaboration companies. in in several be would of in am companies contact global with America. our I been have And outside North We with way

for As would and I base local collaborations But and Europe mentioned follow is for our course. commercialization. America North before, then, Israel would look of first we also there

Ofer. Arnon. more you, Thank Okay. questions two for And

is, Evogene’s and CRISPR’s First please an details more update consortium? one the within on participation provide

what derive you to be. design, place edit probability happening We, CRISPR-X that industry CRISPR – institutions increase genome. so, problems idea at technology in stay than center under Evogene, the conduct facing, to a certain And that precise develop this life to guided is which science by to and one mean or is precise make as part the the that trying the group on guided is to called edit Evogene this all ensure will the that of to will place this want are is RNA CasX consortium is CRISPR-CasX is from Okay, consortium the RNA authority. is innovation of consortium you found will can design academic that mainly try local that we its the focused not together the in capabilities and from using of and AI is something is consortium responsibility. order with companies the more in it will solve And going in and only using the the using Israeli in

focusing details will editing is that And of And the and is projects editing. are explore technology programs GeneRator developing use it. the have far planning to more consortium why genome develop we genome So, we AI from right on earliest from other on the And the technologies inside is this improving use are – one start can that I trait of using the will it through process all our that all Evogene. platform. we benefit and quality members that this to believe this will a should knowhow to

time? five is, – vision your what Ofer, you. Thank And question last for what Okay. years is is the Evogene in

Well, okay.

and important most the So, first is technology.

has AI, and computational you ChemPass Evogene components robust. trends more is And AI on. integrate could and are by all public companies. algorithm our we this subsidiaries, can three I four capture engines, for the our of that it trends companies how stand three it advancing in of - focusing there we AgPlenus, is the I population them huge products I that we wide is think they hub Canonic, that address to be ethics value maybe the core them should order with need believe toward our one for Bio our make to MicroBoost each itself more time new independent this GeneRator main that much already and CPB huge, and the to completely of stay technology, And develop and believe represent one themselves. mean, because companies four four to platform have should continue that they the efficient by And acquired, envision so Lavie are Biomica. the and will – a will challenges AI, really into that biology, be technology systems I definitely and and that each the that new all it focusing data I there to potential with respect can those time on

world-leading really create see in now, The different technology And in successful more are success new as shareholders. I computational can their be of develop lighthouse analyst from could to Evogene through of and I will them new each technology have in definitely well. serve a start to moving a start the subsidiary, not just loyal necessarily like some to our in utilize just areas we subsidiaries already disclose new new value through collaborations. to Evogene set hope one we to four collaborations the the strategic also company going activities our call, generate subsidiaries. as set in In subsidiaries. to addition, as to be activities, of we this company, of are the that years of to and biology. strategic But have, is The the leverage it a they do – that sector we there can will area also Evogene not that subsidiaries five phases

of I expectation have five lot years. the Evogene So, for next from

it Okay. the operator. and hand you, to Ofer back Thank I’ll

you. question ahead. Thank next Geoff Investments. The from of Gilbert Please go is Inukshuk

for Thank today. he you Arnon, review, since potential into call the is especially the were question for appreciate comprehensive and One my you new the markets call on specifically insights the taking talking like Ofer. I about,

go cannabis comment how While enquiries do it’s you like see off, Are done? each with might and your of strategy, can versus medical on for development? sales different have more if medical is I.e. thinking question. couple the a for actual partner somebody the have lines? Maybe you Thanks you recreational taking product a there you partnering of in you years your to field with market direct-to-consumer, MetaYield? my a industry strategies

you Hi. the question. Thank for

So, in to them. structured sides our side, current genetics two work On develop we of genetics go to strategy to the those one relies with cultivators chain value market are on actually. heavily reproduce on cultivating new

about implement to are and we Canonic genetics. trying and into other brand patients the needs it all side, the reaching learning our the the On building to way market

way our building order Canonic working and under products the the developing product expect structure we the reproductive is pharmacy. Israel, and pharmacy subcontractors here we distributors, see Cultivators, first all and producing are Israel the in on with producers, to the get the in in to those the our to brand. here So, in that material genetics so

or genetics order either America our at North the to to all would final Did Going product here out brands or work be Israel that in to patient If approaching products. or in the a local prefer Israel, consumers a way and that need of local in We other would brands. day, product end we would answer products other we that our the get But understand to consumer. the with like those with your it’s would the question? territories, abroad, prefer the Canonic work market. to we Europe in the developed work will and of cultivate in

It did.

see consumers? the getting to So, expect to we Canonic can brand strategies in multiple

on the territories, strategies, depend sure. depends to Right, develop it would

Excellent. Thanks times. Exciting again.

you. Thank

you. Thank

at questions are There this no [Operator time. Instructions] further

Mr. ask call to call would please you conference. I call statement, is Israel, XXXXXXXXXXX. scheduled with Before Ofer a the after call participants begin Haviv two make like that please your go to to his this would X-XXX-XXX-XXXX. In U.S., Mr. please I closing like Internationally, statement? Haviv, hours ahead replay concluding to the In of XX-XXXX-XXX. remind

everyone. updating good Thank today. Yes, I call look all you Thank you progress next day and forward thank the you. joining few for over months. with to you our the

results and fourth participation. Evogene's call. your year Thank you you. for XXXX full concludes conference This quarter Thank

ahead go may disconnect. You and